Not a great fan of Motley Fool but this is their current summary of broker sentiment.
"Should you buy?
Let’s canvas the views of the experts.
Macquarie retained its outperform rating and $326 share price target after CSL reported its results.
Morgans has held firm with its add rating and an improved share price target of $328.20.
UBS stuck with its buy rating and $340 price target.
Citi maintains its a buy rating on CSL shares with a reduced price target from $340 to $325.
Goldman Sachs maintains a neutral rating and has a $296 price target. It describes CSL as “oversold”.
Goldman says:
We continue to believe the shares look oversold (market-relative P/E has de-rated from 2.7x to 1.7x in the last 10 months, and our TP of $296 implies +9% upside from today’s close)."
- Forums
- ASX - By Stock
- News: CSL UPDATE 1-Biotech firm CSL's full-year profit rises on higher plasma collections
Not a great fan of Motley Fool but this is their current summary...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$300.77 |
Change
0.000(0.00%) |
Mkt cap ! $145.3B |
Open | High | Low | Value | Volume |
0.0¢ | $302.30 | $295.20 | $3.388M | 11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 954 | $321.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$242.11 | 300 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 954 | 321.360 |
1 | 36496 | 318.610 |
1 | 100 | 318.600 |
1 | 160 | 316.820 |
2 | 64 | 315.810 |
Price($) | Vol. | No. |
---|---|---|
242.110 | 300 | 4 |
242.120 | 347 | 3 |
280.000 | 3 | 1 |
280.250 | 23 | 1 |
282.990 | 10 | 2 |
Last trade - 10.00am 15/08/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online